Clinical trial · Observational
Examination of Trends in Non-Small Cell Lung Cancer Patients' Medical Study Experiences
Investigating Patients' Medical Study Experiences in Non-Small Cell Lung Cancer Clinical Trials to Identify Influencing Trends
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Medical study participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. Participating in an observational clinical trial may help patients with non-small cell lung cancer since it advances medical knowledge and may improve treatment choices in the future.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Rate of patients who decide to enroll in a non-small cell lung cancer clinical study.
- timeFrame
- 3 months
- measure
- Number of non-small cell lung cancer patients who remain in clinical trial until completion.
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Participant has a diagnosis of non-small cell lung cancer * Patient has self-identified as planning to enroll in a clinical trial for non-small cell lung cancer * Patient is at least 18 years of age Exclusion Criteria: * Inability to perform regular electronic reporting * Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial * Pregnant or lactating woman
References
Publications (3)
- BACKGROUNDKayser G. [Non-small cell lung cancer. New biomarkers for diagnostics and therapy]. Pathologe. 2015 Nov;36 Suppl 2:189-93. doi: 10.1007/s00292-015-0084-1. German. PMID 26391246
- BACKGROUNDDufraing K, Van Casteren K, Breyne J, D'Haene N, Van Campenhout C, Vander Borght S, Zwaenepoel K, Rouleau E, Schuuring E, von der Thusen J, Dequeker E. Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders. BMC Cancer. 2022 Jul 6;22(1):736. doi: 10.1186/s12885-022-09798-5. PMID 35794532
- BACKGROUNDSimeone JC, Nordstrom BL, Patel K, Klein AB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. Future Oncol. 2019 Oct;15(30):3491-3502. doi: 10.2217/fon-2019-0348. Epub 2019 Sep 9. PMID 31497994